Neue Studiendaten zur Primär- und Sekundärprävention des Schlaganfalls

Dieser Beitrag fasst die wichtigsten neuen Erkenntnisse der letzten 3 Jahre zur Prävention des Schlaganfalls zusammen. Bei der Primär- und Sekundärprävention hat sich die Evidenz zur Antikoagulation bei Vorhofflimmern, zur Behandlung asymptomatischer Carotisstenosen und zu symptomatischen intrakraniellen Stenosen erweitert. Mit Asundexian und Milvexian sind 2 neue Faktor-XIa-Inhibitoren zur Schlaganfallprävention derzeit in klinischer Prüfung.

Schlüsselwörter

Orale Antikoagulanzien - Vitamin-K-Antagonisten - Acteylsalicylsäure - Ballondilatation - Stenting - Vorhofflimmern - Carotisstenose

• Literatur

• 1 Davidson KW, Barry MJ, Mangione CM. et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA 2022; 327: 1577-1584
• 2 Svendsen JH, Diederichsen SZ, Højberg S. et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 2021; 398: 1507-1516
• 3 Connolly SJ, Karthikeyan G, Ntsekhe M. et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022; 387: 978-988
• 4 Nolte C, Diener H, Endres M. Faktor-XI-Hemmer – neue Therapeutika in der Prävention von Thromboembolien. Info Neurologie & Psychiatrie 2024; 26: 44-53
• 5 Piccini JP, Caso V, Connolly SJ. et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399: 1383-13190
• 6 Piccini JP, Patel MR, Steffel J. et al. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med 2024;
• 7 Kirchhof P, Toennis T, Goette A. et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023; 389: 1167-1179
• 8 Healey JS, Lopes RD, Granger CB. et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024; 390: 107-117
• 9 McIntyre WF, Benz AP, Becher N. et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: A study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 2024; 149: 981-988
• 10 Keyhani S, Cheng EM, Hoggatt KJ. et al. Comparative effectiveness of carotid endarterectomy vs initial medical therapy in patients with asymptomatic carotid stenosis. JAMA Neurol 2020; 77: 1-12
• 11 Stefanou M-I, Theodorou A, Malhotra K. et al. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. Eur Stroke J 2024; 9: 530-539
• 12 Shoamanesh A, Mundl H, Smith EE. et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400: 997-1007
• 13 Sharma M, Molina CA, Toyoda K. et al. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2024; 23: 46-59
• 14 Diener HC, Rothwell PM. Antithrombotic drugs in secondary stroke prevention: still some way to go. Lancet 2022; 400: 974-975
• 15 Nidorf SM, Fiolet ATL, Mosterd A. et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; 383: 1838-1847
• 16 Kelly P, Lemmens R, Weimar C. et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. Lancet 2024; 404: 125-133
• 17 Li J, Meng X, Shi FD. et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. Br Med J 2024; 385: e079061
• 18 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498
• 19 Steffel J, Verhamme P, Potpara TS. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20: 1231-1242
• 20 Oldgren J, Åsberg S, Hijazi Z. et al. Early versus delayed non-vitamin K antagonist oral anticoagulant Therapy after acute ischemic stroke in atrial fibrillation (TIMING): A registry-based randomized controlled noninferiority study. Circulation 2022; 146: 1056-1066
• 21 Fischer U, Koga M, Strbian D. et al. Early versus later anticoagulation for stroke with atrial Fibrillation. N Engl J Med 2023; 388: 2411-2421
• 22 Grosse GM, Hüsing A, Stang A. et al. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study. Int J Stroke 2023; 18: 1169-1177
• 23 Diener H-C, Grosse GM, Hüsing A. et al. Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study. Eur Stroke J 2024; 9: 696-703
• 24 Chimowitz MI, Lynn MJ, Derdeyn CP. et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003
• 25 Zaidat OO, Fitzsimmons BF, Woodward BK. et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015; 313: 1240-1248
• 26 Gao P, Wang T, Wang D. et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis: The CASSISS randomized clinical trial. JAMA 2022; 328: 534-542
• 27 Sun X, Deng Y, Zhang Y. et al. Balloon angioplasty vs medical management for intracranial artery stenosis: The BASIS randomized clinical trial. JAMA 2024; 332: 1059-1069
• 28 Diener HC, Sacco RL, Easton JD. et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380: 1906-1917
• 29 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 378: 2191-2201
• 30 Geisler T, Poli S, Meisner C. et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 2017; 12: 985-990
• 31 Kamel H, Longstreth WT, Tirschwell DL. et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: The ARCADIA randomized clinical trial. JAMA 2024; 331: 573-581